Please login to the form below

Not currently logged in
Email:
Password:

Eisai/ UCL partnership grows

Eisai is to extend its partnership with University College London, a UK-based university with which the company has been collaborating with for more than 20 years

Eisai is to extend its partnership with University College London (UCL), a UK-based university with which the company has been collaborating with for more than 20 years.

The new phase will see the Eisai and UCL engage in joint research in neurodegenerative disease including biomarker research into neuroinflammation, neurovascular/mitochondria and proteostasis.

During the course of their partnership which began in 1990, Eisai and UCL established an Eisai research facility on the UCL campus and have forged strong co-operative ties through research activities that included the exchange of personnel.

Additionally Eisai said it plans to submit marketing authorisation applications to the regulatory authorities in the US and Europe for perampanel, a first-in-class, highly selective, non-competitive AMPA-type glutamate receptor antagonist that was created through collaborative with UCL research, to complement its marketed products which include Zonegran (zonisamide), Inovelon (rufinamide) and Zebinix (eslicarbazepine acetate).

26th May 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics